FDA tentatively approves Dr. Reddy's first generic injectable lenacapavir for HIV prevention
The FDA has granted tentative approval to Dr. Reddy's generic injectable lenacapavir for HIV prevention, marking a major regulatory milestone for affordable twice-yearly PrEP access in lower-income countries.
The generic formulation is intended for HIV pre-exposure prophylaxis in 120 low- and middle-income countries covered by Gilead's voluntary licensing arrangements, with an agreed price of $40 per person annually and development support from Unitaid, Wits RHI and the Clinton Health Access Initiative.
Initial supplies are expected before the end of 2026 subject to country-level requirements, while the FDA's tentative approval confirms completion of its scientific review but does not permit immediate generic marketing in the United States.
Field | Content |
Article Type | Approvals |
Company | Dr. Reddy's Laboratories |
Product | Generic injectable lenacapavir |
Active Ingredient | Lenacapavir |
Modality | Long-acting HIV capsid inhibitor |
Regulator | U.S. Food and Drug Administration |
Approval Type | Tentative approval |
Approval Announcement Date | 2 November 2026 |
Indication | HIV pre-exposure prophylaxis |
Therapeutic Area | HIV prevention |
Administration Route | Injection |
Dosing Frequency | Twice yearly |
Reference Medicine Developer | Gilead Sciences |
Licensing Framework | Gilead voluntary licence |
Target Markets | 120 low- and middle-income countries |
Agreed Annual Price | $40 per person |
Development Support | Unitaid; Wits RHI; Clinton Health Access Initiative |
Expected Initial Supply | Before the end of 2026 subject to country-level requirements |
US Marketing Status | Tentative approval does not authorise immediate generic marketing in the United States |
Regulatory Significance | FDA tentative approval of the first generic injectable lenacapavir for HIV prevention |
Geographic Scope | Licensed lower-income markets; FDA scientific review conducted in the United States |
What Happened | The FDA granted tentative approval to Dr. Reddy's generic injectable lenacapavir for HIV prevention. |
Why It Matters | The decision supports a pathway toward affordable access to long-acting HIV prevention in countries with substantial unmet prevention needs. |
Regulatory Distinction | Tentative approval confirms the FDA's scientific review outcome but is not full US commercial marketing authorisation. |
Access Significance | The agreed $40 annual price and 120-country licence coverage could support broader access to twice-yearly injectable PrEP. |
Key Takeaway | Dr. Reddy's has achieved a significant regulatory milestone for affordable generic lenacapavir, with initial supply dependent on country-specific requirements. |
What to Watch | Country-level authorisations, procurement commitments, manufacturing scale-up, first shipments and HIV prevention programme adoption. |
Primary Source | Clinton Health Access Initiative |
Primary Source URL | https://www.clintonhealthaccess.org/news/us-fda-approves-first-generic-injectable-lenacapavir-for-hiv-prevention/ |
Relevant Date | 2 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentários